Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + aluminum glycinate + magnesium carbonate
- Development stage
- Unknown
- Lead developer
- Lion Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bufferin A81 is a buffered aspirin combination tablet originally developed by Lion Co., Ltd. It contains 81 mg of aspirin as the active antiplatelet agent, combined with a buffering agent known as dialuminate (a mixture of aluminum glycinate and heavy magnesium carbonate) to mitigate gastrointestinal side effects. Aspirin acts by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing the production of thromboxane A2 and inhibiting platelet aggregation. The product is indicated for the prevention and treatment of cardiovascular and cerebrovascular conditions, including angina pectoris, myocardial infarction, and ischemic stroke, as well as Kawasaki disease. Zhejiang Huahai Pharmaceutical is currently developing a generic version in China.
- Brand names
- Bufferin A81Bufferin combination tablets A81Bufferin 81-mg tabletsBufferin81-mg tabletsBufferin-81-mg tablets
- Other names
- aspirin/aluminum glycinate/magnesium carbonate tablets (II)dihydroxy aluminum aminoacetate, heavy magnesium carbonate and aspirin tablets (II)
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on aspirin + aluminum glycinate + magnesium carbonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + aluminum glycinate + magnesium carbonate.